SPOTLIGHT: Cylene closes $26.3M round

Oncology drug developer Cylene Pharmaceuticals of San Diego has raised $26.3 million in its second round. Coastview Capital led the round, which will fund new research into the company's lead cancer product. Story

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.